

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Structure-guided engineering of type I-F CASTs for targeted gene insertion in human cells

George D. Lampe^{1*}, Ashley R. Liang^{1,5*}, Dennis J. Zhang^{1,6}, Israel S. Fernández^{2,3,#}, Samuel H. Sternberg^{1,4#}

¹Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.

²Ikerbasque, Basque Foundation for Science, Bilbao, Spain.

³Instituto Biofisika (UPV/EHU, CSIC), University of the Basque Country, Leioa, Spain.

⁴Howard Hughes Medical Institute, Columbia University, New York, NY, USA.

⁵Present Address: Tornado Bio, San Francisco, CA, USA.

⁶Present Address: Section of Microbiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.

*These authors contributed equally to this work.

#Co-corresponding authors. E-mail: shsternberg@gmail.com; israel.s.fernandez@gmail.com

25 **ABSTRACT**

26 Conventional genome editing tools rely on DNA double-strand breaks (DSBs) and host
27 recombination proteins to achieve large insertions, resulting in a heterogeneous mixture of
28 undesirable editing outcomes. We recently leveraged a type I-F CRISPR-associated transposase
29 (CAST) from the *Pseudoalteromonas* Tn7016 transposon (*Pse*CAST) for DSB-free, RNA-guided
30 DNA integration in human cells, taking advantage of its programmability and large payload
31 capacity. *Pse*CAST is the only characterized CAST system that has achieved human genomic
32 DNA insertions, but multiple lines of evidence suggest that DNA binding may be a critical
33 bottleneck that limits high-efficiency activity. Here we report structural determinants of target DNA
34 recognition by the *Pse*CAST QCascade complex using single-particle cryogenic electron
35 microscopy (cryoEM), which revealed novel subtype-specific interactions and RNA-DNA
36 heteroduplex features. By combining our structural data with target DNA library screens and
37 rationally engineered protein mutations, we uncovered CAST variants that exhibit increased
38 integration efficiency and modified PAM stringency. Structure predictions of key interfaces in the
39 transpososome holoenzyme also revealed opportunities for the design of hybrid CASTs, which
40 we leveraged to build chimeric systems that combine high-activity DNA binding and DNA
41 integration modules. Collectively, our work provides unique structural insights into type I-F CAST
42 systems while showcasing multiple diverse strategies to investigate and engineer new RNA-
43 guided transposase architectures for human genome editing applications.

44

45 **INTRODUCTION**

46 Canonical CRISPR-Cas systems that have been leveraged for programmable gene
47 editing, such as Cas9 nucleases, cause targeted DNA double-strand breaks (DSBs) that provoke
48 the cell to activate DNA repair mechanisms^{1,2}. Non-homologous end joining (NHEJ) is the most
49 efficient repair pathway in human cells, which leads to indel mutations, and although homology-
50 directed repair (HDR) offers the ability to generate precise modifications or insertions, it is
51 inefficient in most cell types, inaccessible in non-dividing cells, and requires large homology arms
52 for each new insertion site^{3,4}. Furthermore, HDR efficiencies decrease drastically with insertion
53 size, and aberrant editing pathways that occur at non-negligible frequencies can cause large
54 chromosomal truncations and/or rearrangements⁵⁻¹⁰. Second generation editors, including base
55 and prime editors, employ nickase-variant Cas proteins to bypass DSB intermediates, but indel
56 byproducts still arise and edits are generally restricted to single-base pair (bp) changes or small
57 insertions (<50 bp)¹¹⁻¹⁴, thus failing to address the need for large DNA insertion technology.
58 CRISPR-associated transposases (CASTs), on the other hand, leverage a CRISPR-associated
59 DNA targeting module and a transposase effector module that allow for highly specific and
60 programmable insertions, which are both DSB-free and multi-kilobases in size¹⁵⁻¹⁷.

61 To date, four CAST subtypes have been characterized in bacteria: type I-B, I-D, I-F, and
62 V-K^{15,16,18,19}. These subtypes encode unique architectures for both the targeting and integration
63 steps of the transposition pathway: type I CASTs rely on TnsABC proteins for integration and a
64 multi-subunit complex for DNA targeting that includes TniQ and Cascade components (TniQ-

65 Cascade, hereafter simply QCascade), with Cascade itself comprising 3-5 unique protein
66 components in varying oligomeric states^{20–22}; whereas type V-K CASTs rely on only TnsBC for
67 integration^{16,23,24} and a simpler Cas12k-TniQ-S15 co-complex for DNA targeting²⁵. Individual
68 homologs within each of these CAST subtypes also vary in sequence identity^{26,27}, subunit
69 composition and fusion connectivity^{18,24,28}, DNA targeting modules, crRNA guide sequence^{18,26,29},
70 and host factor requirements^{17,25,30}, thus representing a diverse pool of potential starting points
71 for tool development. Although type V-K CASTs are more compact systems in terms of coding
72 size, they exhibit multiple undesirable biochemical properties — including reduced specificity^{31–}
73 ³³, low overall editing efficiencies^{16,31}, and poor product purity^{24,34,35} — that would necessitate
74 extensive optimization for potential research and therapeutic genome engineering applications.
75 In contrast, type I-F CASTs exhibit highly specific and homogeneous integration products, with
76 demonstrably greater efficiencies than types I-B, I-D, and V-K^{15–19,24}.

77 CAST systems have been the focus of extensive structural efforts using cryogenic electron
78 microscopy (cryoEM) in recent years. The type V-K ShCAST system from *Scytonema hoffmannii*
79 has been systematically investigated^{25,36–39}, with a recent report of the holo transpososome
80 architecture that revealed intricacies of the megadalton complex containing Cas12k, TniQ, TnsB,
81 TnsC, single-guide RNA, partial donor and target DNA substrates, and the bacterial host factor
82 S15³⁹. Structural studies of type I-B and I-F CASTs have largely focused on the QCascade DNA
83 targeting module and the accessory TnsC ATPase^{20,21,40–43}, with no structures of the
84 endonuclease-transposase TnsAB module described to date. Intriguingly, QCascade structures
85 exhibit distinct conformations across different systems: type I-B CASTs feature a single TniQ
86 monomer that recruits TnsC to the Cascade-bound target DNA²¹, whereas type I-F CASTs feature
87 a TniQ homodimer that is stably associated with Cascade²⁰. Thus far, two I-F CAST systems from
88 subtypes I-F3a and I-F3b have been deeply characterized — *Vch*CAST (Tn6677) and *Asa*CAST
89 (Tn6900), respectively — both of which are only distantly related to *Pse*CAST (Tn7016), a system
90 that we recently exploited for targeted DNA integration in human cells¹⁷.

91 The *Pse*CAST RNA-guided transposase was identified as a lead candidate for human
92 genome engineering applications through a systematic screen of diverse type I-F CAST systems¹⁷
93 (**Fig. 1a**). Although our first study reported editing activities that reached single-digit efficiencies
94 at genomic target sites, representing a ~100-fold improvement over our original candidate,
95 *Vch*CAST, these efficiencies remain limiting for downstream applications. We hypothesized that
96 identifying bottlenecks in the system would inform more targeted rational engineering,
97 developed several assays to investigate intermediate events and overall integration efficiencies
98 in human cells¹⁷, and then applied these assays to *Vch*CAST and *Pse*CAST, the only type I-F
99 CASTs shown to successfully perform RNA-guided integration in human cells. Intriguingly, while
100 *Pse*CAST promoted comparatively robust DNA integration, it exhibited markedly weaker DNA
101 binding activity relative to *Vch*CAST. We therefore hypothesized that, alongside parallel efforts to
102 engineer and evolve hyperactive transposase variants, the *Pse*CAST QCascade module would
103 represent a promising focus area to improve DNA targeting and thus editing efficiencies.

104 Towards that goal, here we report the cryoEM structure of *Pse*CAST QCascade and the
105 effect of targeted mutations in the PAM- and crRNA-interacting regions on DNA integration.

106 Separately, we leveraged AlphaFold-Multimer to predict protein-protein interactions within the
107 TnsABC co-complex, inspiring the rational design of novel chimeric CAST systems that enable
108 divergent DNA targeting and DNA integration modules to be combined into a single functional
109 system. Collectively, this work establishes multiple biochemically- and structurally-guided
110 approaches to engineer CAST systems for improved editing efficiencies in human cells.

111

112 **RESULTS**

113 **CryoEM structure of PseCAST QCascade complex**

114 We previously demonstrated that *Vch*CAST and *Pse*CAST, two distantly related type I-F
115 CASTs^{17,26}, exhibit distinct DNA binding and integration efficiencies (**Fig. 1a-c**). Given our
116 previous mechanistic and structural studies of the QCascade complex from *Vch*CAST^{20,40}, we
117 hypothesized that structure-guided engineering of the *Pse*CAST QCascade complex might reveal
118 novel interactions and open a path to improve overall integration efficiencies. We therefore
119 purified recombinant *Pse*QCascade after carefully optimizing the expression vector design
120 (**Supplementary Fig. 1**) and set out to determine the cryoEM structure.

121 We incubated the purified *Pse*QCascade complex, which is expected to comprise a
122 1:6:1:2:1 stoichiometry of Cas8:Cas7:Cas6:TniQ:crRNA components (**Fig. 1d**), with a double-
123 stranded DNA (dsDNA) substrate containing a 32-bp target sequence and 5'-CC-3' PAM, and
124 then subjected the sample to electron microscopy. Preliminary cryoEM experiments revealed a
125 homogeneous behavior with multiple views and no apparent disassembly (**Supplementary Fig.**
126 **2a**), and the overall architecture was consistent with other type I-F QCascade complexes,
127 comprising six Cas7 monomers (named hereafter Cas7.1 to Cas7.6) that form a pseudo-helical
128 assembly coating the crRNA molecule (**Fig. 1e**). The Cas8 protein contains two domains: a bulky
129 domain that interacts with Cas7.1 and binds the crRNA 5' end and PAM sequence, and a second
130 α -helical domain that exhibited a dynamic behavior (**Fig. 1f**). Towards the crRNA 3' end (hereafter
131 PAM-distal region), the RNA hairpin is stabilized by Cas6, which also binds the TniQ dimer.
132 Preliminary maps exhibited greater mobility for the TniQ dimer compared to other QCascade
133 components (**Supplementary Fig. 2b,c**). The quality of the maps approaching the TniQ dimer
134 region degrades rapidly, contrasting the excellent map quality for the PAM-adjacent region
135 (**Supplementary Fig. 2d**). Multibody approaches in Relion4 improved the overall resolution, with
136 approximately 2.6 Å and 3.0 Å resolution estimates in the PAM-proximal and PAM-distal regions,
137 respectively (**Methods**).

138 To further characterize the dynamics of the system and confirm the existence of novel
139 interactions, we complemented our multibody analysis in Relion4 with cryoDRGN⁴⁴, a machine-
140 learning approach for cryoEM analysis (**Supplementary Fig. 3**). CryoDRGN revealed multiple
141 populations of the complex, with the TniQ dimer populating a wide range of positions relative to
142 the rest of the complex that pivot around Cas6 and Cas7.6. The dimer adopts an 'open'
143 conformation that lacks any direct interactions with Cas8, as well as multiple intermediate, 'closed'
144 conformations that approach the tip of the Cas8 α -helical domain (**Supplementary Fig. 3b**). In a
145 recent structure of a homologous QCascade complex bound to target DNA, the Cas8 α -helical

146 domain exhibits a different conformation, almost perpendicular to the inner face of the TniQ dimer
147 and aligned with the bulky domain of Cas8²². In our dataset, we did not observe this extended
148 conformation and instead detected alternative TniQ-Cas8 interactions that are established
149 between the most distal end of the TniQ dimer and the apical part of the Cas8 α -helical domain,
150 which were revealed through low-pass filtered maps (**Supplementary Fig. 3c**). Both the TniQ
151 dimer and the Cas8 α -helical domains remain in parallel configurations, with only marginal
152 contacts at the periphery of the complex. Despite the apparent flexibility in this interaction
153 (**Supplementary movie 1 and 2**), the Cas8 α -helical domain is essential for RNA-guided DNA
154 integration activity, as revealed by the complete loss of human cell activity when we replaced the
155 domain with a flexible glycine-serine linker (**Supplementary Fig. 4**).

156

157 **Stabilizing protein-RNA and protein-protein interactions**

158 The overall architecture of the TniQ dimer is similar to the *Vch*CAST QCascade dimer²⁰,
159 with an antiparallel head-to-tail configuration, forming a compact unit that laterally approaches the
160 interface formed by Cas6 and Cas7.6 (**Fig. 2a**). The C-terminal domain of one TniQ monomer
161 interacts with Cas6, and the N-terminal domain of the other TniQ monomer interacts with Cas7.6.
162 At the core of this four-fold interface, the crRNA appears to play a critical role, with residues 40–
163 45 establishing multiple RNA-protein stacking interactions (**Fig. 2b,c**).

164 We hypothesized that crRNA interactions with Cas6, Cas7.1, TniQ.1, and TniQ.2 are
165 crucial for robust QCascade complex formation, and that disrupting them would prevent
166 transposase recruitment and abolish integration activity. We therefore introduced alanine point
167 mutations to disrupt nucleobase-side chain stacking interactions and investigated the resulting
168 effects in human genomic DNA integration assays. Alanine substitutions to Cas6 and TniQ
169 residues contacting the crRNA were well tolerated, whereas a Cas7 R143A mutation (Cas7^{R143A})
170 abolished integration activity (**Fig. 2d**). The crRNA trajectory in the hinge region between Cas7.6
171 and Cas6 differs in *Pse*CAST and *Vch*CAST (**Fig. 2e**), and *Pse*CAST crRNA residue G41 seems
172 to play a key role as an interaction “hub,” establishing coincident contact with TniQ.1, TniQ.2, and
173 Cas7.6 by adopting a unique, extruded conformation.

174 We next explored protein-protein interactions that we similarly hypothesized would
175 contribute to QCascade function, in part by playing a role in downstream transposase recruitment
176 to the target site. The first of these interactions involved a hydrophobic patch on Cas6 cradling
177 hydrophobic residues in the loop connecting TniQ.1 α -helices W262–K275 and F312–S327 (**Fig.**
178 **3a,b**), which is conserved across homologous QCascade complexes, with minor variations.
179 Specifically, a hydrophobic residue in the TniQ.1 connecting loop (I282 in *Pse*CAST, V270 in
180 *Vch*CAST) inserts deeply into the Cas6 hydrophobic patch to anchor the TniQ monomer to the
181 Cascade module (**Fig. 3c**). The cradle structure of this interaction potentially acts as a pivot point,
182 facilitating dynamic TniQ movement. Disruption of these hydrophobic interactions via introduction
183 of charged arginine residues in either TniQ or Cas6 led to a marked reduction in integration
184 efficiencies (**Fig. 3d**). The other TniQ monomer (TniQ.2) interacts electrostatically with Cas7.6 via
185 α -helix Y33–L47 and adjacent residues (**Fig. 3e**). Given the multimeric assembly of Cas7
186 monomers along the crRNA, loop regions observed to interact with TniQ.2 may have pleiotropic

187 functions, possibly participating in Cas7 monomer-monomer interactions (**Supplementary Fig.**
188 **5**). With the goal of selectively perturbing Cas7.6-TniQ.2 interactions to investigate its importance,
189 we avoided mutagenizing residues that might affect the Cas7 monomer-monomer contacts and
190 thus focused on loops A and B (**Supplementary Fig. 5b**). Alanine mutations within the TniQ-
191 interacting regions abolished DNA integration, whereas several mutations within Cas7 had
192 surprisingly little to no impact on overall DNA integration activity (**Fig. 3f**).
193

194 **Protein engineering modulates PAM stringency and improves DNA integration**

195 In comparison to other type I-F CASTs, *Pse*CAST exhibits a remarkably flexible PAM
196 preference, with almost no sequence preference at both the -1 and -2 positions in *E. coli*
197 transposition assays²⁶; this property may lead to a dramatic increase in the effective search space
198 for the 32-bp guide. Inspired by previous work investigating CRISPR-Cas9 activity and PAM
199 search space⁴⁵, we hypothesized that inefficient DNA targeting due to a flexible PAM preference
200 may represent a rate-limiting step in RNA-guided DNA integration, especially within the cellular
201 milieu of human cells, whose genome is ~1000× larger than *E. coli*. We therefore set out to
202 specifically engineer QCascade variants that might exhibit altered PAM specificity and thus direct
203 altered DNA integration efficiencies.

204 After leveraging the excellent quality of our cryoEM map in the area surrounding Cas8, we
205 identified two hydrophobic alanine residues at the center of the PAM-interacting region. In
206 contrast, systems with stricter PAM preferences — *Vch*CAST, *Asa*CAST, and *Pae*Cascade from
207 a *Pseudomonas aeruginosa* type I-F1 CRISPR-Cas system^{26,46} — feature polar residues at the
208 equivalent positions, which allow for hydrogen bonding with specific PAM nucleotides (**Fig. 4a,b**,
209 **Supplementary Fig. 6a**). Based on these observations, we reasoned that mutation of A143 and
210 A144 to residues with greater hydrogen bonding potential might improve PAM stringency, reduce
211 the effective search space, and result in more efficient DNA targeting. We also chose to
212 mutagenize residues 125–127, as this region also interacts with the PAM (**Fig. 4b**,
213 **Supplementary Fig. 6a**). We analyzed the sequence conservation at these PAM-interacting
214 regions and compared *Pse*CAST to other Cascade homologs that have previously exhibited either
215 robust DNA integration activity or stringent PAM preferences (**Supplementary Fig. 6b,c**).
216 Collectively, we designed fifteen Cas8 variants with PAM-interacting mutations, varying from
217 single point mutations at A243 or A244 to larger mutations in which the entire PAM-interacting
218 region was grafted from a homolog.

219 We quantified changes in PAM preference by performing an episomal PAM library screen
220 in HEK293T cells, in which a target plasmid (pTarget) contained an *AAVS1* target site directly
221 downstream of a randomized 4-bp PAM library (**Supplementary Fig. 6d**). After transiently
222 transfecting cells with pTarget, pDonor, and all the necessary protein-RNA expression vectors,
223 we isolated plasmid DNA, sequenced the PAM motifs from all successful integration products,
224 and constructed a consensus motif for each Cas8 variant; in parallel, we also quantified absolute
225 integration efficiencies at the genomic *AAVS1* site, which contains a 5'-CC-3' PAM (**Fig. 4c**). The
226 results revealed that certain mutations led to improvements in integration efficiencies by as much
227 as 3.5-fold, but without a clear correlation between PAM stringency and overall genomic

228 integration activity (**Fig. 4c**). For example, the variant with the greatest improvement in integration
229 activity, Cas8^{R241K,A244S}, actually exhibited a reduced PAM preference, compared to the stronger
230 preference for cytidine in the -2 position with WT Cas8 (**Fig. 4c, Supplementary Fig. 6e**).
231 Interestingly, Cas8^{A243Q,A244N} exhibited decreased PAM preference, whereas when we grafted the
232 entire PAM region from a type I-F1 system (₂₄₁RPAAV₂₄₅>KPQNI), the resulting mutant restored
233 a strong preference for cytidine at the -1. Mutations within the upstream PAM-interacting region
234 (residues 125-127) showed moderate improvements on integration activity, with either unchanged
235 or moderately reduced PAM stringency (**Fig. 4c**). A Cas8^{R241A} mutant with disrupted 'R-wedge,'
236 which normally forms stacking interactions with the -1 PAM position to help unwind dsDNA^{47,48},
237 unexpectedly exhibited both WT integration efficiencies and PAM stringency (**Fig. 4c**).

238 Together, mutational profiling of the PAM-interacting region revealed key residues whose
239 mutation improved integration efficiencies, but the combination of PAM specificity and integration
240 activity results failed to support the hypothesis that PAM promiscuity is a key bottleneck towards
241 achieving higher efficiency *PseCAST* integration activity in human cells (**Fig. 4c, Supplementary**
242 **Fig. 6e**).

243 We also focused on PAM-proximal interactions with the upstream double-stranded DNA
244 region as another potential point of engineering and optimization. Previous work on canonical
245 type I-F1 defense systems revealed key interactions between dsDNA and the N-terminal region
246 of Cas8⁴⁷⁻⁴⁹, with a positively charged vise domain undergoing a conformational change to 'clamp'
247 onto the PAM-adjacent sequence in a non-specific fashion. When comparing *PseCas8* (from type
248 I-F3 *PseCAST*) to *PaeCas8* (from type I-F1 *PaeCascade*; **Supplementary Fig. 7a**), we observed
249 a markedly different conformation of the N-terminus, with the vise domain absent. Given this
250 potential deficiency, we hypothesized that substituting the *PaeCas8* vise domain in *PseCas8*
251 could improve DNA binding affinity and thus CAST activity. However, a thorough screening of
252 chimeric Cas8 constructs for human cell integration activity revealed a clear intolerance of
253 *PseCas8* to sequence perturbations in this region (**Supplementary Fig. 7b**). We pursued
254 additional synthetic strategies to improve DNA binding of *PseQCascade* by fusing a variety of
255 DNA-binding domains to the *PseCas8* N-terminus of *PseCas8* (**Supplementary Fig. 7c**), inspired
256 by engineering strategies previously applied to polymerases^{50,51}, reverse transcriptases⁵², and
257 ligases⁵³. However, these fusions exhibited no improvement relative to WT, and in some cases
258 reduced overall integration efficiencies (**Supplementary Fig. 7c**). Collectively, these experiments
259 suggest that either the DNA binding affinity of *PseCas8* is not a critical bottleneck in the overall
260 transposition pathway, or that the tested variants fail to improve upon the WT activity in this
261 regard.

262

263 **Unfavorable nucleobase positioning along the RNA-DNA heteroduplex**

264 Cascade complexes bind the target DNA by forming a discontinuous RNA-DNA
265 heteroduplex in 6-bp segments^{47,54}, and we could clearly resolve RNA-DNA base pairs for the first
266 4 segments engaged by Cas7 monomers within the *PseQCascade* complex, but the remaining
267 two segments featured weaker RNA density and no DNA density. Density for the RNA-DNA
268 heteroduplex across the first 3 segments (crRNA residues 9 to 26) was exceptionally good, with

269 clear separation within base pairs and features compatible with a local resolution beyond 3 Å. We
270 were therefore able to accurately model RNA-DNA interactions to a high level of confidence in
271 these regions of the map. The resulting view revealed peculiarities in the base-pair geometry, with
272 acute divergence from ideal values in some base pairs. The third and fourth base pair within each
273 segment exhibited severe deviation from ideal planarity values (buckling), while the first and fifth
274 base pair exhibited exacerbated propeller twist deviations. Only the second base pair across
275 distinct segments exhibited geometric and hydrogen-bonding distance values closer to
276 energetically favored conditions (**Fig. 4d-h**).

277 Type I-F Cascade complexes bind the target DNA, such that the two-stranded β -sheet
278 'finger' motif of each Cas7 monomer engages the crRNA to flip out every sixth nucleotide of the
279 32-nt spacer, thereby preventing RNA-DNA basepairing^{20,47}. We hypothesized that finger motif
280 residues involved in this nucleotide dislocation might promote the consistent distortion of adjacent
281 base pairs, and to explore this effect, we introduced Cas7 mutations intended to relax this
282 distortion, hoping to promote energetically favorable hydrogen-bonding geometries and stabilize
283 the RNA-DNA heteroduplex. Taking advantage of the high local resolution around this region
284 (**Supplementary Fig. 8a,b**), we identified numerous bulky hydrophobic residues—including I69,
285 L70, and L224—that were not highly conserved across nearby homologs (**Supplementary Fig.**
286 **8c**), and subjected them to site-directed mutagenesis.

287 After generating the desired Cas7 mutations, we performed genomic DNA integration
288 experiments in HEK293T cells at the AAVS1 locus (**Fig. 4i**). Intriguingly, the Cas7 heteroduplex-
289 interacting residues, though not highly conserved, appeared to have low tolerance for mutations.
290 While Cas7^{L224F} and various valine mutations exhibited near-WT integration efficiencies, all other
291 mutations, including Cas7^{I69P}, resulted in detrimental impacts on DNA integration (**Fig. 4i**).
292 Intriguingly, L70H, which would theoretically recapitulate a stacking interaction observed in our
293 previous *VchCAST* structure²⁰, completely ablated integration activity (**Fig. 4i**). Together, the
294 intolerance to perturbations in the Cas7 finger domain suggests these nucleobase kinking
295 interactions may in fact be necessary for proper successful DNA integration.

296

297 **Structure-based engineering of chimeric CAST systems.**

298 Rational engineering of *PseQ*Cascade yielded only moderate improvements in integration
299 activity, suggesting a non-trivial path forward to overcome the apparently weak DNA binding
300 activity in human cells¹⁷. Although recent studies shed light on the kinetics of Cascade target
301 search and recognition^{55,56}, the intermediate steps of Cascade complex formation, TniQ-Cascade
302 association, and 3D-diffusion remain poorly understood, particularly in human cells. *PseCAST*
303 was originally identified through a homolog screen that investigated both overall integration
304 activity and several subunit-specific properties: crRNA processing, TnsB-donor DNA interactions,
305 and QCascade and TnsC-mediated transcriptional activation¹⁷. Through this screening process,
306 *VchCAST* (Tn6677) and *PseCAST* (Tn7016) were the only two systems that yielded detectable
307 DNA integration in human cells, despite exhibiting distinct subunit-specific activities. Based on
308 these results, we hypothesized that natural CAST systems may be unlikely to possess optimal
309 human cell properties across all recombinant components, and we therefore set out to design

310 chimeric CAST systems that would enable ‘crosstalk’ between otherwise orthogonal components.
311 Our specific goal was to combine the most active DNA targeting and DNA integration machineries
312 derived from divergent CASTs (**Fig. 5a**).

313 To identify robust DNA targeting homologs, we tested DNA binding activity across 20 type
314 I-F CASTs via transcriptional repression in *E. coli*^{40,57} (**Supplementary Fig. 9a**). Surprisingly,
315 QCascade complexes from only two systems — *Vch*CAST and Tn7005 — exhibited RFP
316 repression under the tested conditions, with only weak activity from *Pse*CAST and Tn7000
317 (**Supplementary Fig. 9b**). Yet when we tested the overall DNA integration activity of *Vch*CAST
318 and *Pse*CAST at the exact same sites used for transcriptional repression, we again observed
319 greater integration activity for *Pse*CAST, mirroring our results in human cells¹⁷ (**Supplementary**
320 **Fig. 9c**). This reinforced the conclusion that the weak DNA targeting activity of *Pse*CAST may
321 impose a lower ceiling on achievable DNA integration efficiencies in diverse cell types, despite
322 having co-evolved with a highly active transposition (TnsABC) module.

323 We sought to address this potential bottleneck by combining the TnsABC machinery from
324 *Pse*CAST with the QCascade machinery from *Vch*CAST. We previously demonstrated that
325 intrinsic CAST modularity precludes simply mixing and matching components from evolutionary
326 diverse systems²⁶, but we were emboldened to attempt a more nuanced approach by taking
327 advantage of recent high-resolution structures^{21,39}, predicted structures via structural
328 alignments⁵⁸, and AlphaFold-multimer⁵⁹ predicted structures. (**Fig. 5b, Supplementary Fig. 10**).
329 In particular, a model for the putative TnsABC co-complex from *Pse*CAST featured the expected
330 heptameric arrangement of TnsC, similar to our empirical structures for *Vch*CAST⁴⁰, while also
331 revealing predicted interactions between *Pse*TnsC and the C-terminus of *Pse*TnsB that were
332 reminiscent of the TnsB ‘hook’ described for type V-K ShCAST^{37,39} (**Fig. 5b, Supplementary Fig.**
333 **10a**). This model, in conjunction with experimentally determined type V-K structures and
334 biochemical studies of Tn7⁶⁰, led us to speculate that the C-terminal tail of TnsB functions a key
335 mediator of TnsC interactions, and that the specificity of CAST transpososome assembly would
336 be dictated in part by cognate TnsB-TnsC interactions. Importantly, we hypothesized that
337 reengineering this interaction would enable the TnsAB and donor DNA components from one
338 CAST system to be combined with the QCascade and TnsC components from an orthogonal
339 CAST system.

340 To test this hypothesis, we designed 16 chimeric TnsAB constructs in which different
341 lengths of the *Pse*TnsB C-terminus were substituted with corresponding residues from the
342 *Vch*TnsB C-terminus (**Fig. 5c**). These variants were then screened for RNA-guided DNA
343 integration activity in *E. coli*, in conjunction with *Vch*QCascade and *Vch*TnsC, but with a pDonor
344 containing transposon ends compatible with *Pse*TnsB (**Fig. 5d**). As expected, given our previous
345 work²⁶, WT *Pse*TnsAB, lacking any chimeric substitutions, showed undetectable activity when
346 combined with *Vch*CAST DNA targeting machinery (**Fig. 5e**). Remarkably, however, several
347 chimeric TnsAB designs were able to robustly rescue activity, showing up to ~10% integration
348 efficiencies (**Fig. 5e**). These designs, which only reprogrammed 20 – 29 amino acids in the C-
349 terminus of *Pse*TnsAB exhibited graft points between the *Pse* and *Vch*TnsB sequence in an
350 unstructured region that links the “hook” region of the C-terminus to the remainder of the protein

351 sequence (**Fig. 5c**); furthermore, when comparing this region to solved type V-K complexes, it is
352 located in a similar region as the 52-residue long “flexible linker” that was unresolved³⁹. Together,
353 we conclude that substitutions in this region minimize disruptions to the overall protein fold, while
354 nonetheless providing a chimeric hook that is compatible for cognate interactions with *VchTnsC*.

355 We next set out to investigate if this chimeric design is reciprocal; that is, can we rescue
356 DNA integration activity when combining *PseQCascade* and *PseTnsC* with a chimeric *VchTnsAB*
357 design? After designing and cloning similar constructs, we were indeed able to detect integration
358 activity with the converse combination (**Supplementary Fig. 11a**). Furthermore, when we applied
359 these chimeric designs to a broader range of homologous TnsAB variants and their cognate mini-
360 Tn donor substrates, we also observed integration activity for chimeric designs derived from
361 additional transposon variants, denoted Tn7005 and Tn7015²⁶. Intriguingly, TnsAB chimeras
362 derived from Tn7010 and Tn7011 showed no evidence of activity (**Supplementary Fig. 11b**),
363 suggesting that some CASTs may require targeted screening to identify tolerable chimeric graft
364 points. Next, we explored whether this engineering approach could also generate compatible
365 chimeras between divergent CRISPR-associated transposons, candidate Type I-F (*VchCAST*)
366 and Type V-K (*ShCAST*) systems, each of which comprise distinct transposase architectures and
367 likely arose from unique domestication events²³. TnsB variants derived from *ShCAST* exhibited
368 low, but detectable levels of activity as well (**Supplementary Fig. 11b,c**); when we investigated
369 the transposon insertion orientation preference for type I/V CAST chimeras, we observed that
370 chimeras in which the TnsB was derived from *ShCAST* exhibited a “T-LR” insertion preference,
371 as typically observed in previous *ShCAST* studies^{16,35}, while type I-F CASTs exhibit a “T-RL”
372 preference^{15,26} (**Supplementary Fig. 11d**). Together, these results reveal that rational, structure-
373 guided engineering of precise regions of CAST systems can overcome the natural orthogonality
374 of diverse systems, enabling novel genome editing designs.

375

376 DISCUSSION

377 The unexpected paradox of poor DNA binding and strong overall integration activity of
378 *PseCAST* (**Fig. 1b,c, Supplementary Fig. 9**), inspired us to determine cryoEM structures of
379 *PseQCascade* and pursue rational engineering methods to improve DNA targeting. Given the
380 unique phenomenon among CAST systems to harbor ‘homing’ crRNAs that target conserved,
381 often essential, genes within the host genome^{18,26,28,29}, CAST-derived CRISPR modules may have
382 been naturally selected for weak DNA binding relative to their defense-associated CRISPR-Cas
383 counterparts, thereby reducing transcriptional repression of these essential genes. This possibility
384 underscores the need to develop a comprehensive understanding of all molecular requirements
385 and intermediate steps within the CAST transposition pathway.

386 The structure of *PseQCascade* resembles previously determined DNA-bound type I-F
387 CAST structures^{20,22}, but several knowledge gaps still limit a complete understanding of the
388 mechanistic requirements for RNA-guided transposition. First, the functional relevance of the
389 Cas8 helical bundle remains a mystery. When comparing between three distinct, DNA-bound
390 QCascade structures^{20,22}, three different conformational states of the helical bundle have been
391 observed: a state in which the domain is unresolved, suggesting a conformationally dynamic

392 mode related to the open versus closed state of the overall QCascade complex²⁰; a state in which
393 the domain is resolved, with close contact to the PAM-distal DNA²²; and a state in which the helical
394 bundle is resolved but does not contact TniQ or the PAM-distal DNA (**Fig. 1e,f**). Despite this
395 heterogeneity, our deletions experiments clearly indicate that the helical bundle is crucial for
396 overall DNA integration to occur (**Supplementary Fig. 4**). Another area that will require future
397 study is the manner in which the QCascade complex binds TnsC, since these interactions have
398 not yet been captured for a type I-F CAST system; mutations in Cas7 that theoretically disrupt
399 Cas7.6 interactions with TniQ.2 appear to be tolerated (**Fig. 3e,f**). Although unexpected, this lends
400 credence to the possibility that only one of the two TniQ monomers present in type I-F CAST
401 complexes interacts with TnsC, which is supported by similar CAST structures from type I-B and
402 type V-K systems in which only one TniQ is present with TnsC at the target site (**Supplementary**
403 **Fig. 10**)^{21,25,39}. Further *in vitro* biochemical studies, combined with structural insights into the holo
404 transpososome, will be necessary to shed light on these mechanistic aspects, including the extent
405 to which the helical bundle may regulate TnsC recruitment, and thus the targeting discrimination
406 between on- and off-target sites during CAST transposition⁴⁰.

407 Beyond defining structural requirements for transposition, our QCascade structure
408 revealed potential targets for rational engineering, most notably within the PAM interacting regions
409 of Cas8. The presence of alanine residues at this interface, rather than polar residues,
410 differentiates *Pse*CAST from homologous type I-F CAST systems (**Supplementary Fig. 6a**).
411 Interestingly, one of these homologous systems — *Vch*CAST — exhibited higher DNA binding
412 activity than *Pse*CAST in both human cells and *E. coli* (**Fig. 1c, Supplementary Fig. 9**), leading
413 us to hypothesize that reinstating polar residues might stabilize DNA-protein interactions, thereby
414 increasing DNA binding activity and integration efficiency. Mutation of even one of these alanine
415 residues yielded QCascade variants with integration efficiencies 2- to 3-fold above wild-type, but
416 interestingly, these changes did not accompany concomitant increases in PAM stringency (**Fig.**
417 **4b**). On the other hand, our episomal PAM screen in human cells revealed a wild-type ‘CN’
418 preference that had not previously been observed in *E. coli*, and we hypothesize that this
419 difference may result from the larger DNA search space in the human cell milieu. The quality of
420 our cryoEM maps also provided a detailed view of RNA-DNA base-pairing interactions, enabling
421 visualization of energetically unfavorable nucleobase positioning along the heteroduplex (**Fig. 4d-**
422 **h**). Close analysis of the surrounding Cas7 residues implicated several hydrophobic side chains
423 in enforcing this positioning (**Supplementary Fig. 8**), and we therefore introduced mutations with
424 less bulky side chains to potentially stabilize heteroduplex formation. Interestingly, however, most
425 Cas7 variants completely abolished integration activity (**Fig. 4i**), suggesting that these mutations
426 adversely affected DNA binding and/or QCascade complex formation.

427 Alongside our efforts at engineering specific *Pse*CAST components for DNA integration
428 activity improvements, we considered a parallel path that would instead leverage pre-existing
429 components from homologous CAST systems. Our previous experiments revealed the orthogonal
430 properties of diverse type I-F CAST systems, which precluded mixing and matching of
431 homologous components into single systems²⁶, but we hypothesized that a more nuanced,
432 structure-guided approach could reveal unique opportunities for the construction of synthetic

433 chimeric designs that would retain key protein-protein interactions necessary for transposition. To
434 this end, we leveraged AlphaFold⁵⁹ to generate predicted structures of TnsA-TnsB interacting with
435 a heptameric TnsC ring (**Fig. 5b**), and based on the resemblance to previously determined type
436 V-K transpososome structures (**Supplementary Fig. 10a**)³⁹, we envisioned that reprogramming
437 the TnsB C-terminus could uncover functional chimeric CASTs. This hypothesis was borne out
438 with data demonstrating that chimeric CASTs, in which the DNA targeting module of *Vch*CAST
439 was combined with the DNA integration module of *Pse*CAST, functioned robustly for RNA-guided
440 DNA integration (**Fig. 5**). Next, we further extended these chimeric designs to a variety of type I-
441 F systems, and we demonstrated the first example of coordinated activity between type I-F and
442 type V-K CAST machineries (**Supplementary Fig. 11**). Based on these promising results, we
443 expect that future modifications will enable additional chimeric starting points for future
444 engineering, such as at the TniQ–TnsC interface (**Supplementary Fig. 10b,c**).

445 The ability to coordinate targeted integration with transposase proteins derived from
446 unique families²³ opens the door to novel, diverse chimeric CAST designs that can sample
447 combinatorial sequence spaces unexplored by evolution. With growing evidence that additional
448 CAST subtypes can be leveraged for genome editing applications in human cells^{61–63}, the ability
449 to exchange modules with ease may be key for future CAST engineering efforts. Collectively, our
450 work showcases diverse, structure-guided approaches to understand and improve CAST
451 function, and opens the door to a far greater combinatorial space for leveraging CASTs systems
452 as genome editing tools.

453

454 **METHODS**

455 **Protein purification**

456 The TniQ-Cascade complex from *PseCAST* (*PseQCascade*) was overexpressed and
457 purified as previously described²⁰, with the following modifications. All proteins were codon
458 optimized and placed downstream of consensus RBS sequences, and TniQ contained an N-
459 terminal 10xHis-TEV tag. The minimal CRISPR array was encode upstream of *cas7* and
460 contained a 32 bp spacer targeting the *AAVS1* locus (see **Supplementary Table 1** for detailed
461 plasmid sequences). After overnight expression at 0.5 mM IPTG, cell pellets were resuspended
462 in QCascade lysis buffer (50 mM Tris-Cl, pH 7.5, 700 mM NaCl, 0.5 mM PMSF, EDTA-free
463 Protease Inhibitor Cocktail tablets (Roche), 1 mM dithiothreitol (DTT), 5% glycerol) and lysed by
464 sonication. Lysates were clarified by centrifugation at 15,000 x g for 30 min at 4 °C. Initial
465 purification was performed by immobilized metal-ion affinity chromatography with NiNTA Agarose
466 (Qiagen) using NiNTA wash buffer (50 mM Tris-Cl, pH 7.5, 700 mM NaCl, 10 mM imidazole, 1
467 mM DTT, 5% glycerol) and NiNTA elution buffer (50 mM Tris-Cl pH 7.5, 700 mM NaCl, 300 mM
468 imidazole, 1 mM DTT, 5% glycerol). The sample was further purified by size exclusion
469 chromatography over a Superose 6 Increase 10/300 column (GE Healthcare) equilibrated with
470 QCascade storage buffer (20 mM Tris-Cl, pH 7.5, 700 mM NaCl, 1 mM DTT, 5% glycerol).
471 Fractions were pooled, concentrated, snap frozen in liquid nitrogen, and stored at -80 °C. TEV
472 cleavage was not performed.

473

474 **Plasmid construction**

475 Bacterial expression plasmids for *PseQCascade* were codon-optimized for *E. coli* and
476 synthesized by GenScript. For human cell transfections, genetic components encoding *PseCAST*
477 proteins were codon-optimized for human cells, synthesized by GenScript, and cloned into
478 pcDNA3.1 expression vectors. All CAST constructs were cloned into plasmids using a
479 combination of restriction digestion, ligation, Gibson assembly, and Golden Gate assembly. All
480 PCR fragments for cloning were generated in-house using Q5 DNA Polymerase (New England
481 Biolabs (NEB)) and gel purified using Qiagen Gel Extraction.

482 To clone the 4N PAM library used for HEK293T cell episomal integration assays, two
483 overlapping oligos containing 'NNNN' were phosphorylated with T4 PNK (NEB) and hybridized at
484 95 °C for 2 min before cooling to room temperature. The resulting oligoduplex was ligated into a
485 target plasmid vector predigested with BsmBI (55 °C for 2 h) using T4 DNA ligase (NEB). Cloning
486 reactions were transformed into chemically competent NEB Turbo *E. coli*, plated on agar plates
487 with the appropriate antibiotic to grow overnight, and inoculated in 5 uL LB media and antibiotic
488 for approximately 7 h. Colony counting was then performed to ensure sufficient library diversity.
489 Plasmids were then purified using Qiagen Miniprep columns verified by a combination of Sanger
490 sequencing (Azenta/Genewiz) and whole-plasmid nanopore sequencing (Plasmidsaurus), and
491 ultimately characterized by high-throughput sequencing (Illumina).

492

493 **CryoEM structure determination.**

494 Purified *PseQCascade* was serially diluted in a modified buffer (20 mM Tris-Cl, pH 7.5,
495 200 mM NaCl, 1 mM DTT) for initial imaging experiments. Target DNA (NTS: 5'-
496 TTCATCAAGCCATTGGACCGCCACAGTGGGGCCACTAGGGACAGGATTGGTGACCTTCGC
497 CTTGACGGCCAAAA-3', TS: 5'-TTTTGGCCGTCAAGGCGAAGCTGAAAAGCAATGAAGCCAA
498 AGCGTCCTGTAAGGCGGTCCAATGGCTTGATGAA-3') was duplexed by mixing the NTS and
499 TS in equimolar concentrations, heated to 95° C, and then cooled to room temperature. 50 μ M
500 aliquots were then snap frozen. Purified *PseQCascade* aliquots were incubated with a 5X molar
501 excess of target DNA for 10 min at room temperature with a total reaction volume of 50 μ L. The
502 complex (2-4 μ M range) was initially imaged in a Talos L120C (Thermo Fisher) electron
503 microscope equipped with a LaB₆ electron source and a Ceta-M camera. Negative staining
504 experiments were carried out using uranyl-formate solution at 0.75% (w/v) in water. CF-400
505 (EMS) continuous carbon grids were activated for 30 s using a Ar/O₂ gas mix plasma at 25 W
506 using a Solarus2 plasma cleaner (Gatan). Immediately after plasma activation, 3 μ L of the
507 *PseQCascade*/DNA complex at concentrations of 1, 2 and 4 μ M were applied to the activated
508 grids. After 1 min incubation, the excess solution was gently blotted away, and 3 μ L of 0.75%
509 uranyl-formate solution was added for an additional 1 min incubation. Excess staining solution
510 was blotted away and the grids were left on the bench drying for 5 min. Grid screening revealed
511 well stained, homogeneous, and dispersed particles with a circular shape compatible in
512 dimensions and shape with the estimated molecular size of the complex, as well as showing
513 similarities with previously reported images of other Cascade complexes (**Supplementary Fig.**
514 **2a**).

515 We chose the 1 μ M concentration grid for manual collection of 10 negative staining images
516 (pixel size 2.5 Å/pixel, 1 s exposure, -2 to -3 μ m defocus) for exploratory class-2D analysis in
517 Relion4. The resulting negative staining C2D averages confirmed the homogeneity of the sample
518 and its potential for high-resolution (**Supplementary Fig. 2a, left**). Next, we explored the behavior
519 of the complex under cryogenic conditions using the negative stain conditions as a reference
520 starting point. We vitrified UltraAu foil 1.2/1.3 'Gold' grids (Quantifoil) using a VitroBot Mark IV
521 (Thermo Fisher) set up to 100% humidity and 4 °C. The sample concentration was in the 2–4 μ M
522 range. Grids were plasma cleaned with the same protocol described for the negative staining
523 grids, and after application of 3 μ L solution, the grids were blotted and plunged frozen in liquid
524 ethane. VitroBot settings were: blot force -5, drain and waiting time 0 with blotting times varying
525 between 2.5 to 3.5 s. Following these parameters, we froze 8 grids, 4 grids at 2 μ M concentration
526 and 4 grids at 4 μ M concentration. 2 grids, one at 2 μ M and another at 4 μ M concentration were
527 transferred to a cooled 910 side entry holder (Gatan) for screening under cryogenic conditions in
528 the same Talos L120C microscope used for negative staining using similar imaging conditions.
529 Both grids showed good ice distribution, with the 2 μ M grid showing better particle distribution and
530 contrast in ice. Using SerialEM, we collected 10 images with similar settings as in negative
531 staining experiments for exploratory reference-free C2D analysis in Relion4 under cryogenic
532 conditions (**Supplementary Fig. 2a, middle**). The resulting C2D averages were promising, with
533 distinctive and multiple views of the complex. The grid was recovered and stored for high

534 resolution data collection in a Titan Krios G3i electron microscope equipped with a
535 BioQuantum/K3 energy filter and direct detection.

536 High resolution data was collected at high magnification with 2x hardware binning in the
537 K3 detector (0.6485 Å/pixel size after binning) at a fluence of $\sim 20e^-/\text{pixel/s}$ and 1 s exposure time
538 for a total dose of $\sim 50 e^-/\text{Å}^2$. Defocus range was adjusted to vary between -0.8 to -2 μm , and the
539 total number of K3 fractions was adjusted to 50. 24 h collection on the recovered grid yielded
540 $\sim 22,000$ images which were on-the-fly motion corrected in Relion4 with ctf estimation in ctfind4.
541 Image processing was integrally done in Relion 4 and cryoDRGN. First, we manually selected
542 100 images for Laplacian picking, which yielded $\sim 4,000$ particles that were normalized and
543 extracted with 8 times binning. Fast C2D analysis using the VDAM algorithm generated C2D
544 averages in multiple orientations that were selected and used as training set for Topaz, used
545 through the Relion wrapper. Using the optimized trained model from Topaz, the full dataset of
546 $\sim 22,000$ images yielded ~ 1.5 million particles that after two C2D steps using T parameters of 3
547 and then 6 was reduced to $\sim 667,000$ particles. ArnA contamination accounted for the bulk of the
548 eliminated particles. Next, we refined the reduced dataset using a filtered map of *VchQ*Cascade
549 as reference. We did not perform alignments with this initial classification (K20, tau fudge T=6).

550 We identified multiple classes with damaged or poorly aligned particles, a class without
551 the TniQ dimer, and a dominating class with better features. A re-extraction step was then
552 performed with the recenter option activated and at 4x binning (2.594 Å/pixel). After selection of
553 2D class averages showing secondary structure features, an ab-initio 3D model was
554 reconstructed using the Stochastic Gradient Descent (SGD) algorithm with all selected particles
555 from the class 2D job (K4, tau fudge T=3). A second 3D refinement produced a consensus
556 refinement in the 5 Å range that upon inspection showed clear secondary features and substantial
557 heterogeneity at the PAM distal region hosting the TniQ dimer. A soft-mask (10 pixel extension,
558 8 pixel soft edge and initial threshold of 0.002) was used for 3D classification without alignment
559 using 20 classes and T parameters 3, 6 and 8. A minor population ($\sim 8\%$ of the particles) of
560 Cascade without TniQ was identified and removed from the dataset, together with poorly aligned
561 or damaged particles, reducing the total dataset to $\sim 128,000$ particles. Re-refinement of this
562 dataset after re-extraction to binning 2 (~ 1.2 Å/pixel) produced a sub-3Å map, but exacerbated
563 heterogeneity of the TniQ dimer region was evident.

564 Using focused classification of this region of the map produced multiple classes without
565 clear discrete states, suggesting continuous heterogeneity. Before applying a multibody
566 approach, we re-refined the $\sim 128,000$ particle dataset after refining the ctf parameters (defocus
567 values per particle and astigmatism per micrograph) followed by Bayesian particle polishing for
568 signal decay and local particle movement correction. We defined via soft masking (6 pixel mask
569 extension, 6 pixel soft edge decay, initial threshold 0.002) three rigid body groups: the first body
570 included Cas8, and the first Cas7 monomer (Cas7.1), the second body contained Cas7
571 monomers 2 to 5, and the third body included the TniQ dimer, Cas6, Cas7.6, and the crRNA 3'-
572 proximal hairpin. Residual rotation priors were defined to 10 degrees with translation offset of 2
573 pixels. We designed two wide masks: one (body 1) covering the best part of the map and including
574 Cas8, the first five Cas7 proteins, and surrounding densities including the corresponding sections

575 of the crRNA-DNA heteroduplex; and a second soft mask (body 2) covering Cas7.6, Cas6, and
576 the TniQ dimer. Multibody refinement produced maps with exceptional quality for each body, with
577 clear sub 3Å features for the Cas8 and the Cas7 regions. The maps for the PAM-distal body,
578 including the TniQ dimer, improved substantially, but residual heterogeneity remained, especially
579 at the distal end of the TniQ dimer.

580 We used ModelAngelo⁶⁴ for initial model building using the improved maps from the
581 multibody analysis. With default options and sequence information from the cloned constructs,
582 ModelAngelo correctly built approximately 90% of the residues. Manual inspection of the built
583 model corrected limited errors and completed areas where the resolution did not allow accurate
584 placement of side chains. The built models were refined against the multibody maps
585 independently, first with phenix refine (secondary structure restrain activated) and then with
586 Refmac5, adjusting the experimental/ideal geometry weights manually to avoid overfitting.
587 CryoDRGN analysis was performed with the final set of ~128,000 particles used for multibody
588 analysis in Relion. This set of particles was re-extracted to a box size of 128 pixels and an initial
589 training in 1 dimension (Zdim=1) was performed. After assessing the homogeneity of this set of
590 particles, 3 different training were performed with 2, 4 and 8 dimensions (Zdim=2, 4 and 8).
591 Principal component analysis (PCA), UMAP, and K-means clustering dimensionality reduction
592 techniques were used to explore the derived latent spaces, producing similar results irrespective
593 of the Zdim used. We perform a final training with particle re-extracted to 256 pixels size and Zdim
594 2 and 8. Exploration of the latent space derived from these training revealed multiple
595 conformations of the TniQ dimer, as shown in **Supplementary Figure 3**.

596

597 **Mammalian cell culture and transfections**

598 HEK293T cells were cultured at 37 °C and 5% CO₂ and maintained in DMEM media with
599 10% FBS and 100 U/mL of penicillin and streptomycin (Thermo Fisher Scientific). 24 h before
600 transfection, a 48-well plate was coated with poly-D-lysine (Thermo Fisher Scientific) and seeded
601 with 10,000 cells per well. Cells were transfected with DNA mixtures and 1 µL of Lipofectamine
602 2000 (Thermo Fisher Scientific) per the manufacturer's instructions. Transcriptional activation and
603 integration assays were performed as previously described¹⁷. For plasmid-based PAM library
604 assays, cells were co-transfected with the following *PseCAST* CAST plasmids: 200 ng pTnsAB,
605 50 ng pTnsC, 75 ng pQCascade, 100 ng pCRISPR (crRNA), 200 ng pDonor, and 100 ng pTarget
606 (4N PAM library). Cells were harvested 4 days after transfection using previously described
607 methods¹⁷.

608

609 **Analysis of HEK293T integration assays**

610 Genomic integration assays were analyzed as previously described¹⁷. In brief, 5 µL of
611 genomic lysate (10% of total lysate volume) was used for 2 rounds of PCR. In the first PCR, a
612 forward primer was used that anneals to the AAVS1 locus, and a reverse primer was used that
613 anneals to both the AAVS1 locus and a primer binding site in the donor DNA (see **Supplementary**
614 **Table 3** for oligonucleotide sequences). These oligos included 5' overhangs encoding read 1 and
615 read 2 Illumina adapters. In the second PCR, 'universal' primers were used, which anneal to the

616 read 1 and read 2 sequences and append unique index sequences and the remaining Illumina
617 adapter sequences for next generation sequencing. Samples were then pooled, gel purified, and
618 sequenced on a NextSeq 500/550 with at least 75 cycles in read 1. The relative abundance of
619 reads that contain a *PseCAST* transposon end sequence (representing an integration read) vs.
620 downstream AAVS1 sequence (unintegrated read) was calculated.

621 For the episomal PAM library assay, samples were prepared as above except a different
622 forward oligo was used that anneals directly upstream of the degenerate PAM library in PCR 1,
623 such that we would capture both the PAM sequence and the presence of the transposon end
624 sequence with the forward read (see **Supplementary Table 3** for oligonucleotide sequences).
625 PCR 1 cycles were reduced to 15 cycles. After Illumina sequencing, reads were filtered to have
626 a transposon end sequence, thus representing a PAM library member which was successfully
627 targeted by *PseCAST* for DNA integration. The input library was sequenced as well, to calculate
628 enrichment and depletion scores. Library members were then ranked by their enrichment values
629 (proportion of output library / proportion of input library). The top 10% of library members were
630 used to generate a consensus WebLogo (Version 2.8.2, 2005-09-08, weblogo.berkeley.edu) for
631 the PAM preference of each Cas8 variant. All library members and their associated enrichment
632 values were used to generate PAM wheels using Krona⁶⁵.

633

634 ***E. coli* repression and integration assays**

635 *E. coli* transcriptional repression assays were performed as previously described^{40,57}, with
636 some minor modifications. In brief, an *E. coli* strain expressing mRFP from the chromosome, a
637 gift from L. S. Qi, was transformed with pQCascade. We initially attempted to use pQCascade
638 plasmids with a strong J23119 promoter, but due to toxicity associated with strong *PseQCascade*
639 expression, we switched to a weaker J23101 promoter for all pQCascade constructs. We
640 designed crRNA sequences to target the template strand of mRFP proximal to the 5' end of the
641 coding region (60 bp downstream of the mRFP start codon). Two replicates were performed for
642 each unique transformation, and relative mRFP repression was analyzed as previously
643 described⁴⁰.

644 Integration assays were performed as previously described^{15,40}, with the following
645 modifications. Although J23101 promoters were used for QCascade, J23119 promoters were still
646 used for constitutive expression of all TnsABC cassettes, as there was no observed toxicity. In
647 brief, TnsABC expression vectors harboring donor DNA (pDonor-TnsABC) encoded a *tnsA-tnsB-*
648 *tnsC* operon downstream of a strong constitutive promoter (J23119), as well as a mini-transposon
649 donor DNA of 0.9 and 1.2 kb in length for *VchCAST* and *PseCAST*, respectively, all on a pUC19
650 backbone. Strains harboring medium-strength J23101 promoter-controlled pQCascade
651 constructs were first made chemically competent, followed by duplicate transformations with
652 pDonor-TnsABC and lysate generation for qPCR after an 18 h incubation at 37 °C. Lysates were
653 analyzed via qPCR, as previously performed^{15,40}.

654

655 **Data availability**

656 Cryo-EM maps and models will be deposited on EMDB and PDB and released upon publication.
657 Source data for protein gels are included as **Supplementary Fig. 12**.

658

659 **Author Contributions**

660 G.D.L., A.R.L., and S.H.S. conceived of and designed the project. G.D.L. purified *PseQCascade*.
661 G.D.L. and A.R.L. performed all cellular experiments and cellular experimental analyses, with the
662 exception of *E. coli* repression and integration assays, which were performed by D.J.Z and A.R.L.
663 I.S.F. collected cryoEM data and performed structure determination. G.D.L., A.R.L., I.S.F., and
664 S.H.S. discussed the data and wrote the manuscript, with input from D.J.Z.

665


666 **Acknowledgements**

667 We thank Z. Akhtar for laboratory support, R.T.K. for assistance in mammalian assay design and
668 cloning, L. F. Landweber for qPCR instrument access, the Columbia Stem Cell Initiative Flow
669 Cytometry Core, the JP Sulzberger Columbia Genome Center for NGS support, and the CryoEM
670 facility of the St. Jude Children's Research Hospital in Memphis, Tennessee, USA where the
671 cryoEM high resolution data was collected. Some of this work was performed at the National
672 Center for CryoEM Access and Training (NCCAT) and the Simons Electron Microscopy Center
673 located at the New York Structural Biology Center is supported by the NIH Common Fund
674 Transformative High Resolution Cryo-Electron Microscopy program (U24 GM129539,) and by
675 grants from the Simons Foundation (SF349247) and NY State Assembly. S.H.S. was supported
676 by NIH grant DP2HG011650, a Pew Biomedical Scholarship, a Sloan Research Fellowship, an
677 Irma T. Hirschl Career Scientist Award, and a generous startup package from the Columbia
678 University Irving Medical Center Dean's Office and the Vagelos Precision Medicine Fund.

679


680 **FIGURES**

681



682

683 **Figure 1 | CryoEM structure of the TniQ-Cascade (QCascade) complex from *PseCAST*.** a,
 684 Phylogenetic tree of type I-F CRISPR-associated transposons (CASTs), adapted from a previous
 685 publication²⁶. Systems with previously solved QCascade structures are marked with red arrows,
 686 while *PseCAST* is marked with a green arrow. Phylogenetic clades are colored. b, Experimental
 687 design to investigate both DNA binding and overall integration activities for CAST systems in
 688 human cells¹⁷. DNA binding is extrapolated from two different transcriptional activation assays,
 689 one in which VP64 is fused to Cas7 (left), and one in which VP64 is fused to TnsC (right). Overall
 690 integration efficiencies are measured via amplicon sequencing. c, Comparison of *VchCAST* and
 691 *PseCAST* across different assays in human cells. Although *PseCAST* exhibits consistently weak
 692 transcriptional activation compared to *VchCAST*, its absolute integration activity is approximately
 693 two orders of magnitude greater. DNA integration data is adapted from a previous publication¹⁷.
 694 d, Operonic architecture of *PseCAST* components from the *PseCAST* transposon, with genes
 695 encoding the QCascade complex labeled accordingly. e, Left, dominant reference-free 2D
 696 cryoEM class averages. Right, cryoEM densities with colored map regions corresponding to Cas8
 697 (blue), Cas7 monomers 1-6 (light blue), Cas6 (purple), TniQ monomers 1-2 (orange, yellow),
 698 crRNA (gray), and target DNA (red) indicated. f, Refined model for the Cas8 α -helical domain
 699 and its positioning relative to the TniQ dimer interface.




700

701 **Figure 2 | The role of crRNA in the PAM-distal region of *PseQCascade*.** **a**, Overall view of the
 702 cryoEM reconstruction of the *PseCAST* QCascade complex. **b**, Magnified view of the dashed
 703 region in **a**, highlighting the cryoEM density (colored and semi-transparent) for interactions
 704 between the indicated crRNA nucleotides and protein subunits. **c**, Magnified view of the dashed
 705 regions in **b**, highlighting interactions between the crRNA and Cas6 (left), TniQ.1 (middle), and
 706 both TniQ.2 and Cas7.6 (right). Key interacting residues are labeled. **d**, Normalized RNA-guided
 707 DNA integration efficiency at AAVS1 in HEK293T cells, as measured by amplicon sequencing.
 708 The indicated alanine mutations were designed to perturb specific RNA-protein interactions
 709 highlighted in **c**, and were compared to WT. NT, non-targeting crRNA. Data are shown as mean
 710 \pm s.d. for $n=3$ biologically independent samples. **e**, Comparison of the crRNA conformation
 711 within the PAM-distal region, adjacent to the site of RNA hairpin stabilization by Cas6, for *VchCAST*
 712 (PDB: 6PIJ) and *PseCAST* (this study). The region around nucleotide G41 exhibits a distinct
 713 configuration for *PseCAST*, likely affecting the behavior of the adjacent TniQ dimer.

714

715




716

717 **Figure 3 | TniQ recruitment to the Cas6-Cas7.6 interface of Cascade requires hydrophobic**
 718 **and electrostatic interactions.** **a**, Overall view of the *PseCAST* QCascade complex, oriented to
 719 highlight the TniQ dimer (dark/light orange). **b**, Magnified view of the region indicated in **a**, showing
 720 how TniQ.1 (dark orange) interacts with a hydrophobic cavity on Cas6. The two visual renderings
 721 are colored either by Cas6 surface (purple, top) or hydrophobicity (bottom). **c**, Comparison of the
 722 hydrophobic interactions between TniQ.1 and Cas6 in *PseCAST* (left) and *VchCAST* (right, PDB:
 723 6PIJ), with residues labeled. **d**, Normalized RNA-guided DNA integration efficiency at *AAVS1* in
 724 HEK293T cells, as measured by amplicon sequencing. The indicated arginine point mutations
 725 were designed to perturb TniQ.1-Cas6 hydrophobic interactions. NT, non-targeting crRNA. **e**,
 726 Magnified views of hydrogen bonding (top) and electrostatic (bottom) interactions between Cas7.6
 727 (blue) and TniQ.2 helix (yellow). **f**, Normalized RNA-guided DNA integration efficiency at *AAVS1*
 728 in HEK293T cells, as measured by amplicon sequencing. Alanine mutations perturbing Cas7.6-
 729 TniQ interactions are generally tolerated. Data in **d**, **f** are shown as mean \pm s.d. for n=3 biologically
 730 independent samples.


731

732



733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753

Figure 4 | Structural and functional consequences of PAM and target DNA recognition by *PseQCascade*. **a**, Top, overall view of the *PseQCascade* QCascade complex, oriented to highlight the target DNA recognition. **Bottom**, magnified views of the PAM binding pocket, with Cas8 and DNA shown in blue and red, respectively. Residues A243 and A244 lack any base-specific, hydrogen-bonding interactions with the DNA. **b**, Normalized genomic integration efficiencies at AAVS1 for the indicated Cas8 mutants (top), plotted above the WebLogo for PAM preferences in the -1 and -2 positions (bottom) derived from integration into pTarget. (For additional PAM specificity data, see **Supplementary Fig. 6e**.) Integration efficiency data are shown as mean \pm s.d. for n=3 biologically independent samples. **c**, Magnified view of the experimental cryoEM density map around Cas7.1 and Cas7.2, showing interactions with the crRNA (gray) and DNA target strand (TS, red). NTS, DNA non-target strand. **d**, Overlay of the refined atomic model and cryoEM density (semi-transparent) for the seed region of QCascade bound to the DNA target strand. **e**, Schematic representation showing angles for the first five RNA-DNA base pairs (BP 1–5) within the R-loop. **f**, View of the RNA-DNA heteroduplex at right, highlighting the unfavorable base-pairing surrounding flipped out nucleobases within the first 18 base pairs of the R-loop. **g**, Magnified view of the RNA-DNA heteroduplex segments aligned at the flipped out base pair, revealing consistent unfavorable angles at the adjacent base pairs. **h**, Normalized RNA-guided DNA integration efficiency at AAVS1 in HEK293T cells for the indicated Cas7 mutations, as measured by amplicon sequencing. Data are shown as mean \pm s.d. for n=3 biologically independent samples.



754

755 **Figure 5 | AlphaFold-guided engineering of TnsABC to generate chimeric CAST systems.**

756 **a**, Schematic showing the approach to generate a chimeric CAST system by combining optimal

757 DNA targeting and DNA integration machineries from distinct CAST systems. **b**, AlphaFold-

758 generated structure prediction of the TnsABC co-complex from *PseCAST*. The C-terminal “hook”

759 region of TnsB that putatively interact with TnsC is marked. **c**, Visualization of select TnsB graft

760 points within the predicted *PseTnsABC* structure. Residues where *Pse-Vch* chimerism was

761 introduced are colored in blue, and the three top performing graft points (V585, S589, Q594;

762 *PseTnsB* numbering) from panel **e** are labeled. **d**, Experimental workflow to test chimeric TnsAB

763 constructs for RNA-guided DNA integration activity. *E. coli* BL21(DE3) cells containing a pEffector

764 encoding *VchQCascade* and *VchTnsC* were transformed with a plasmid encoding a mini-

765 transposon (mini-Tn) and TnsAB, with TnsAB derived from either *VchCAST*, *PseCAST*, or a

766 chimeric combination thereof. Integration efficiency was measured by qPCR (bottom). **e**, DNA

767 integration efficiencies for each tested TnsAB chimera. The amino acid listed represents the

768 position at which the reading frame was grafted from *PseTnsB* (red) to *VchTnsB* (blue). “Custom”

769 denotes a variant in which multiple different *VchTnsB* sequences were substituted (see


770 **Supplementary Table 2** for details). Data are shown as mean for n=2 biologically independent

771 samples.

772

773 **SUPPLEMENTARY FIGURES**


774



775

776 **Supplementary Figure 1 | Purification of Qcascade from PseCAST (Tn7016).** **a**, The two
777 schematized expression plasmids (left) encode *E. coli* codon-optimized PseCAST Qcascade
778 genes and a crRNA cassette, with a strong ribosome binding site (half-circle) upstream of each
779 protein-coding gene. After transformation of BL21(DE3) cells and IPTG induction, PseQcascade
780 was purified via Ni-NTA affinity chromatography and size exclusion chromatography (SEC).
781 Codon-optimized expression plasmids were used after the native operon failed to generate
782 detectable Qcascade complexes after SEC. **b**, SEC chromatogram of PseQcascade showing 2
783 distinct peaks. **c**, SDS-PAGE gel of representative Ni-NTA elution fractions that were pooled and
784 used for SEC. Qcascade subunits are labeled. **d**, SDS-PAGE gel of both peaks from SEC.
785 Elutions from peak 1, marked with a red dashed box, were pooled and used for cryoEM.
786

787



788

789 **Supplementary Figure 2 | CryoEM imaging, data processing, and model refinement. a,**

790 Preliminary sample characterization for cryoEM grid optimization. Left, Talos L120C microscope


791 analysis showing exemplary negative staining micrograph (left) and cryogenic micrograph (right).

792 Corresponding reference-free 2D class averages from particles obtained from 10 images are

793 shown below each image, with a calibrated pixel size of 2.5 Å. Right, two grids from the Talos


794 L120C screening were recovered and loaded into a Titan Krios G3i microscope, and a large

795 dataset was collected at a pixel size of 0.644 Å. Two images at different defoci are shown with
796 their corresponding CTF images (inset). Reference-free 2D class averages are shown on the
797 right, with multiple different views revealing details compatible with protein secondary structure.
798 **b**, Image processing workflow implemented in Relion4 for high-resolution structure determination.
799 Briefly, from left to right: an ab-initio 3D model was reconstructed after selection of 2D class
800 averages; using this as a reference, a consensus refinement was generated; inspection of this
801 preliminary map revealed heterogeneity, especially in the region of the TniQ dimer (**Methods**).
802 However, after unbinning and multiple rounds of 3D refinements, the map still exhibited residual
803 heterogeneity in the region adjacent to the Cas6 protein, suggesting mobility of the TniQ dimer
804 with respect to Cascade. To improve the maps and to analyze TniQ dynamics, two masks were
805 designed (**Methods**), yielding improved the densities and B-factors for the first body, but the
806 second body exhibited a significant improvement in terms of resolution and general density
807 quality. **c**, Fourier Shell Correlation (FSC) curves for the half-maps and model-maps. **d**, Local
808 resolution depictions of the final map before and after the multibody approach.
809



810


811 **Supplementary Figure 3 | Visualization of TniQ dimer dynamics with cryoDRGN.** a,
812 cryoDRGN analysis, using the same set of particles (~128,000) identified using Relion4
813 classifications, revealed dynamics of the TniQ dimer and uncovered multiple conformational
814 states. We trained cryoDRGN on our dataset with multiple values of the zdim (2, 4 and 8), and
815 found that the derived latent space for different runs was similar. Shown is a principal component
816 analysis of the latent space derived from the run at zdim = 2. b, Segmentation of this latent space
817 via k-mean clustering revealed multiple TniQ dimer conformations: an 'open' position, in which the
818 TniQ dimer is distant from the Cas8 α -helical domain (cluster 3, green); an intermediate position,
819 where the distal end of the TniQ dimer marginally contacts the Cas8 α -helical domain (cluster 6,
820 grey); and a compact conformation, in which the TniQ dimer closely approaches the Cas8 α -
821 helical domain (cluster 8, pink). In all cryoDRGN-generated maps, the Cas8 α -helical domain
822 remains in a similar position and conformation. with only the TniQ dimer exhibiting pronounced
823 fluctuations
824



825

826 **Supplementary Figure 4 | Cas8 α -helical domain deletion abolishes RNA-guided DNA**
827 **integration.** a, Comparison of select regions of the DNA-bound QCascade complex from
828 *VchCAST* (left, PDB: 6PIJ) and *PseCAST* (right), including the crRNA (grey), target DNA (red),
829 and Cas8 (blue). The Cas8 α -helical domain from *PseCAST* (residues 274–423) is shown in light
830 blue, and was replaced with a flexible, 10-amino acid GS linker in subsequent integration assays.
831 b, Normalized efficiency of RNA-guided DNA integration at *AAVS1*, tested in HEK293T cells and
832 measured by amplicon sequencing (**Methods**). Experiments used WT Cas8 and either a non-
833 targeting (NT) or targeting (T) crRNA, or a targeting crRNA and Cas8 mutant, in which residues
834 N274–K423 were replaced with a 10-amino acid GS linker. Data are shown as mean \pm s.d. for
835 $n=3$ independent biological samples.


836



837

838 **Supplementary Figure 5 | Cas7 loops chosen to selectively perturb Cas7-TniQ.2**
839 **interactions.** a, View of overall PseCAST QCascade complex, with specific regions for panel b
840 highlighted. b, Magnified view of the different Cas7 loop interactions. Loop C participates in
841 interactions at the interface between Cas7 monomers (left) and was therefore left intact. Amino
842 acid sidechains in loops A and B (pink) that interact more closely with TniQ.2 were selected for
843 mutagenesis, as detailed in **Figure 3e,f**.

844



845

846 **Supplementary Figure 6 | Experimental design and results for PAM library screening with**

847 **Cas8.** **a**, Visualization of PAM binding pockets for diverse type I-F Cascade complexes (from left

848 to right): *PseCAST* (this study), *AsaCAST* (PDB: 7U5D), *VchCAST* (PDB: 6PIJ), and *PaeCascade*

849 (PDB: 6NE0)⁴⁷. The top inset shows core PAM-interacting residues; the bottom inset shows the

850 wedge residue and additional interacting residues. **b**, Amino acid sequence conservation within

851 PAM-interacting regions of *PseCas8*, with the WebLogo derived from a multiple sequence

852 alignment (MSA) of 66 homologs; the *PaeCas8* WT sequence is shown below. **c**, MSA of the

853 same regions from **b**, shown for diverse type I-F Cas8 homologs from both CAST and canonical

854 type I-F1 CRISPR-Cas systems. Conserved residues are colored in blue. **d**, Mammalian PAM

855 library assay workflow. A target plasmid (pTarget) was generated that contains an *AAVS1* target


856 flanked by a 4-bp randomized PAM library. Individual Cas8 mutants were screened in each

857 transfection via a plasmid-based integration assay, in which junction PCR and next-generation

858 sequencing revealed PAM sequences enriched within integration products (**Methods**). **e**, Detailed

859 PAM library data for all active Cas8 variants, showing the identity of the mutation(s) (top),


860 WebLogo of the top 10% of enriched library members (middle), and PAM wheel⁶⁵ of all library
861 members (bottom)⁶⁵. The PAM wheel is displayed with the inner and outer rings representing the
862 -1 and -2 PAM positions, respectively.
863



864

865 **Supplementary Figure 7 | Investigating integration activity via engineering DNA-binding**
866 **ability of Cas8.** **a**, Comparing N-terminal regions of *PaeCas8* (PDB: 6NE0) and *PseCas8*. While
867 *PaeCas8* (left) shows a vise domain clamped around the dsDNA backbone, *PseCas8* shows an
868 unstructured region at the N-terminus that does not exhibit clear dsDNA backbone interactions.
869 **b**, Normalized RNA-guided DNA integration efficiency at *AAVS1* in HEK293T cells as measured
870 by amplicon sequencing, for a panel of chimeric Cas8 designs in which the N-terminus of
871 *PaeCas8* (type I-F1 CRISPR-Cas system, green) was grafted onto the N-terminus of *PseCas8*
872 (type I-F3 *PseCAST*, blue); the amino acid residue listed at left indicates the graft point (*PseCas8*
873 numbering). All chimeric designs tested were non-functional for DNA integration. **c**, Normalized
874 RNA-guided DNA integration efficiency at *AAVS1* in HEK293T cells as measured by amplicon
875 sequencing, for a panel of Cas8 fusions designed to improve DNA binding affinity. Thirteen unique
876 archaeal 7 kDa DNA-binding proteins⁶⁶, two helix–hairpin–helix DNA binding motifs ('HhH')⁶⁷, and
877 one binding domain from *Pyrococcus abyssi* DNA ligase⁵² ('Ligase DBD') were tested as N-
878 terminal *PseCas8* fusions, compared to non-targeting (NT) and targeting (T) controls with WT
879 Cas8. Data in **b** and **c** are shown as mean for n=2 biologically independent samples.
880

881



882

883 **Supplementary Figure 8 | Detailed view of Cas7 interactions with the RNA-DNA**

884 **heteroduplex. a**, View of overall *PseQCascade* complex, with the five similar Cas7-crRNA

885 interactions highlighted. **b**, Visualization of Cas7 residues that interact with the crRNA at each


886 flipped out nucleobase; residues with bulky and hydrophobic sidechains are highlighted and

887 labeled. **c**, *PseCas7* sequence conservation at residues in panel **b**, from a multiple sequence

888 alignment of 98 homologs; the WT sequence is shown below the x-axis. Specific residues

889 selected for functional investigation are marked with red arrows.

890




891

892 **Supplementary Figure 9 | DNA binding and integration activity of diverse CAST systems in**

893 ***E. coli*.** **a**, Schematic of *E. coli* transcriptional repression and DNA integration assays to
894 investigate CAST-encoded QCascade activity in bacteria. Using an engineered *E. coli* strain that
895 constitutively expresses mRFP and sfGFP⁵⁷, transformation of⁵⁷. a QCascade expression plasmid
896 driven by a medium-strength J23101 promoter leads to target DNA binding (red triangle) and
897 mRFP repression. Alternatively, when cells are co-transformed with QCascade, TnsABC, and
898 pDonor, RNA-guided DNA integration occurs at the mRFP target site. **b**, Bar graph showing the
899 fold change in mRFP fluorescence for each CAST-encoded QCascade system, relative to a
900 control experiment lacking QCascade (Δ QCascade); **VchCAST** and **PseCAST** are highlighted in
901 bold text. CAST systems are colored by phylogenetic clade, as shown in **Fig. 1a**. **c**, Bar graph
902 comparing DNA integration activity for **VchCAST** and **PseCAST** at the same mRFP target site
903 used for repression assays, as measured by qPCR. As observed in human cells, **PseCAST** yields
904 higher levels of DNA integration activity despite exhibiting apparent weaker QCascade-based
905 DNA targeting and repression. Data in **b,c** are shown as mean for n=2 independent biological
906 samples.


907

908



909


910 **Supplementary Figure 10 | Structural inspiration for the rational design of chimeric CAST**
911 **systems.** **a**, The holo transpososome structure from type V-K ShCAST system (PDB 8EA3), with
912 a magnified view (right) showing how the C-terminal hook of TnsB docks into the TnsC ATPase.
913 **b**, The QCascade-TnsC structure from type I-B *Pmc*CAST system (PDB 8FF4), with a magnified
914 view (right) showing the N-terminus of a monomeric TniQ interacting with the TnsC ATPase. **c**,
915 Predicted QCascade-TnsC structure from type I-F CAST, based on previous modelling⁴⁰ but with
916 PDB ID: 7U5D, for which the PAM-distal DNA is better resolved. The magnified view (right)
917 highlights the putative TniQ-TnsC interface, with the N-terminus of just one TniQ monomer within
918 the dimeric arrangement interacting with the TnsC ATPase.
919



920

921 **Supplementary Figure 11 | Additional chimeric TnsB designs are functional for RNA-**
 922 **guided DNA integration. a**, Investigating reciprocal chimeric designs to coordinate transposition
 923 between *Pse*QCascade-TnsC and *Vch*TnsAB. WT TnsAB sequences for both *Vch*CAST and
 924 *Pse*CAST and three unique chimeric inspired by the most active variants in **Fig. 5e** (variants
 925 V585, S589, and Q594) were tested. Only chimeric TnsAB variants enabled coordinated DNA
 926 integration activity when combining *Pse*QCascade and *Pse*TnsC with *Vch*TnsAB and *Vch* mini-
 927 transposons. **b**, Exploring chimeric CASTs across multiple type I-F systems. Chimeric TnsAB
 928 variants enable coordinated transposition when combining *Vch*QCascade-TnsC with TnsAB
 929 constructs sourced from diverse Type I-F CASTs; Tn numbers were defined previously²⁶. **c**,
 930 Designing chimeric CASTs across evolutionarily distinct CAST families. Chimeric *Sh*CAST TnsB
 931 constructs (inspired by functional chimeric *Pse*TnsABs) can coordinate low levels of transposition
 932 between type I-F and type V-K CAST systems. For chimera 1, only one of two biological replicates
 933 exhibited detectable integration. **d**, Insertion site orientation preference of *Vch*CAST, *Pse*CAST
 934 TnsAB chimeras, and *Sh*CAST TnsB chimeras. *Vch*CAST TnsAB and *Pse*CAST TnsAB chimeras
 935 adopt the common T-RL preference; *Sh*CAST TnsB chimeras invert the insertion site orientation
 936 preference, adopting the previously observed T-LR preference for *Sh*CAST systems¹⁶. Data
 937 shown as mean for n=2 independent biological samples. Chimeras 1, 2, and 3 for all homologs
 938 are listed in **Supplementary Table S2**.

939



940

941 **Supplementary Figure 12 | Uncropped protein gels.** **a**, Uncropped image used for
942 **Supplementary Figure 1c**. The regions shown are marked with dashed boxes. **b**, Uncropped
943 image used for **Supplementary Figure 1d**. The regions shown are marked with a dashed box.

944

945 **Supplementary Movie 1 | Conformational transitions revealed by Relion Multibody analysis**
946 **defining two bodies.** The first body included Cas8, the DNA-RNA duplex, and all Cas7
947 monomers; the second body included the TniQ dimer, Cas6, and the corresponding fragment of
948 the crRNA interacting with Cas6.

949
950 **Supplementary Movie 2 | CryoDRGN analysis of *PseQCascade* flexibility visualized**
951 **through k-means clustering of the latent space.** Morphing between the two most populated
952 states after segmentations into 20 clusters is shown.

953

954 **SUPPLEMENTARY TABLES**

955

956 **Table S1. Description and sequence of plasmids used in this study.**

957 **Table S2. Sequence of chimeric TnsAB protein sequences used in this study.**

958 **Table S3: Oligonucleotides used for amplicon sequencing in this study.**

959

960 **REFERENCES**

- 961 1. Branzei, D. & Foiani, M. Regulation of DNA repair throughout the cell cycle. *Nat. Rev. Mol.*
962 *Cell Biol.* **9**, 297–308 (2008).
- 963 2. Heyer, W.-D., Ehmsen, K. T. & Liu, J. Regulation of Homologous Recombination in
964 Eukaryotes. *Annu. Rev. Genet.* **44**, 113–139 (2010).
- 965 3. Pawelczak, K. S., Gavande, N. S., VanderVere-Carozza, P. S. & Turchi, J. J. Modulating
966 DNA Repair Pathways to Improve Precision Genome Engineering. *ACS Chem. Biol.* **13**,
967 389–396 (2018).
- 968 4. Kanca, O. *et al.* An efficient CRISPR-based strategy to insert small and large fragments of
969 DNA using short homology arms. *eLife* **8**, e51539 (2019).
- 970 5. Zuccaro, M. V. *et al.* Allele-Specific Chromosome Removal after Cas9 Cleavage in Human
971 Embryos. *Cell* **183**, 1–15 (2020).
- 972 6. Adikusuma, F. *et al.* Large deletions induced by Cas9 cleavage. *Nature* **560**, E8–E9 (2018).
- 973 7. Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR–
974 Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* **36**, (2018).
- 975 8. Leibowitz, M. L. *et al.* Chromothripsis as an on-target consequence of CRISPR–Cas9
976 genome editing. *Nat. Genet.* **53**, 895–905 (2021).
- 977 9. Nahmad, A. D. *et al.* Frequent aneuploidy in primary human T cells after CRISPR–Cas9
978 cleavage. *Nat. Biotechnol.* **40**, 1807–1813 (2022).
- 979 10. Tsuchida, C. A. *et al.* Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T
980 cells. *Cell* **186**, 4567–4582.e20 (2023).
- 981 11. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a
982 target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**, 420–424
983 (2016).
- 984 12. Kim, Y. B. *et al.* Increasing the genome-targeting scope and precision of base editing with
985 engineered Cas9-cytidine deaminase fusions. *Nat. Biotechnol.* **35**, 371–376 (2017).

- 986 13. Gaudelli, N. M. *et al.* Programmable base editing of T to G C in genomic DNA without DNA
987 cleavage. *Nature* **551**, 464–471 (2017).
- 988 14. Anzalone, A. V. *et al.* Search-and-replace genome editing without double-strand breaks or
989 donor DNA. *Nature* **576**, 149–157 (2019).
- 990 15. Klompe, S. E., Vo, P. L. H., Halpin-Healy, T. S. & Sternberg, S. H. Transposon-encoded
991 CRISPR–Cas systems direct RNA-guided DNA integration. *Nature* **571**, 219–225 (2019).
- 992 16. Strecker, J. *et al.* RNA-guided DNA insertion with CRISPR-associated transposases.
993 *Science* **364**, 48–53 (2019).
- 994 17. Lampe, G. D. *et al.* Targeted DNA integration in human cells without double-strand breaks
995 using CRISPR-associated transposases. *Nat. Biotechnol.* **42**, 87–98 (2023).
- 996 18. Saito, M. *et al.* Dual modes of CRISPR-associated transposon homing. *Cell* **184**, 2441-
997 2453.e18 (2021).
- 998 19. Hsieh, S. & Peters, J. E. Discovery and characterization of novel type I-D CRISPR-guided
999 transposons identified among diverse Tn7-like elements in cyanobacteria. **51**, 765–782
1000 (2023).
- 1001 20. Halpin-Healy, T. S., Klompe, S. E., Sternberg, S. H. & Fernández, I. S. Structural basis of
1002 DNA targeting by a transposon-encoded CRISPR–Cas system. *Nature* **577**, 271–274
1003 (2020).
- 1004 21. Wang, S., Gabel, C., Siddique, R., Klose, T. & Chang, L. Molecular mechanism for Tn7-like
1005 transposon recruitment by a type I-B CRISPR effector. *Cell* **186**, 4204-4215.e19 (2023).
- 1006 22. Park, J. U. *et al.* Multiple adaptations underly co-option of a CRISPR surveillance complex
1007 for RNA-guided DNA transposition. *Mol. Cell* **83**, 1827-1838.e6 (2023).
- 1008 23. Faure, G. *et al.* CRISPR–Cas in mobile genetic elements: counter-defence and beyond.
1009 *Nat. Rev. Microbiol.* **17**, 513–525 (2019).
- 1010 24. Vo, P. L. H., Acree, C., Smith, M. L. & Sternberg, S. H. Unbiased profiling of CRISPR RNA-
1011 guided transposition products by long-read sequencing. *Mob. DNA* **12**, 1–17 (2021).

- 1012 25. Schmitz, M., Querques, I., Oberli, S., Chanez, C. & Jinek, M. Structural basis for the
1013 assembly of the type V CRISPR-associated transposon complex. *Cell* **185**, 4999-5010.e17
1014 (2022).
- 1015 26. Klompe, S. E. *et al.* Evolutionary and mechanistic diversity of Type I-F CRISPR-associated
1016 transposons. *Mol. Cell* **82**, 616-628.e5 (2022).
- 1017 27. Roberts, A., Nethery, M. A. & Barrangou, R. Functional characterization of diverse type I-F
1018 CRISPR-associated transposons. *Nucleic Acids Res.* **50**, 11670–11681 (2022).
- 1019 28. Rybarski, J. R., Hu, K., Hill, A. M., Wilke, C. O. & Finkelstein, I. J. Metagenomic discovery of
1020 CRISPR-associated transposons. *Proc. Natl. Acad. Sci. U. S. A.* **118**, (2021).
- 1021 29. Petassi, M. T., Hsieh, S. & Peters, J. E. Guide RNA Categorization Enables Target Site
1022 Choice in Tn7-CRISPR-Cas Transposons. *Cell* **183**, 1757-1771.e18 (2020).
- 1023 30. Walker, M. W. G., Klompe, S. E., Zhang, D. J. & Sternberg, S. H. Novel molecular
1024 requirements for CRISPR RNA-guided transposition. *Nucleic Acids Res.* **51**, 4519–4535
1025 (2023).
- 1026 31. Vo, P. L. H. *et al.* CRISPR RNA-guided integrases for high-efficiency, multiplexed bacterial
1027 genome engineering. *Nat. Biotechnol.* **39**, 480–489 (2021).
- 1028 32. Rubin, B. E. *et al.* Species- and site-specific genome editing in complex bacterial
1029 communities. *Nat. Microbiol.* **7**, 34–47 (2022).
- 1030 33. George, J. T. *et al.* Mechanism of target site selection by type V-K CRISPR-associated
1031 transposases. *Science* **382**, (2023).
- 1032 34. Strecker, J., Ladha, A., Makarova, K. S., Koonin, E. V. & Zhang, F. Response to Comment
1033 on “RNA-guided DNA insertion with CRISPR-associated transposases”. *Science* **368**, 1–2
1034 (2020).
- 1035 35. Tou, C. J., Orr, B. & Kleinstiver, B. P. Precise cut-and-paste DNA insertion using engineered
1036 type V-K CRISPR-associated transposases. *Nat. Biotechnol.* (2023) doi:10.1038/s41587-
1037 022-01574-x.

- 1038 36. Park, J. U. *et al.* Structural basis for target site selection in RNA-guided DNA transposition
1039 systems. *Science* **373**, 768–774 (2021).
- 1040 37. Park, J. U., Tsai, A. W. L., Chen, T. H., Peters, J. E. & Kellogg, E. H. Mechanistic details of
1041 CRISPR-associated transposon recruitment and integration revealed by cryo-EM. *Proc.*
1042 *Natl. Acad. Sci. U. S. A.* **119**, 1–9 (2022).
- 1043 38. Querques, I., Schmitz, M., Oberli, S., Chanez, C. & Jinek, M. Target site selection and
1044 remodelling by type V CRISPR-transposon systems. *Nature* (2021) doi:10.1038/s41586-
1045 021-04030-z.
- 1046 39. Park, J. U. *et al.* Structures of the holo CRISPR RNA-guided transposon integration
1047 complex. *Nature* **613**, 775–782 (2023).
- 1048 40. Hoffmann, F. T. *et al.* Selective TnsC recruitment enhances the fidelity of RNA-guided
1049 transposition. *Nature* **609**, 384–393 (2022).
- 1050 41. Jia, N., Xie, W., de la Cruz, M. J., Eng, E. T. & Patel, D. J. Structure–function insights into
1051 the initial step of DNA integration by a CRISPR–Cas–Transposon complex. *Cell Res.* **30**,
1052 182–184 (2020).
- 1053 42. Wang, B., Xu, W. & Yang, H. Structural basis of a Tn7-like transposase recruitment and
1054 DNA loading to CRISPR-Cas surveillance complex. *Cell Res.* **30**, 185–187 (2020).
- 1055 43. Li, Z., Zhang, H., Xiao, R. & Chang, L. Cryo-EM structure of a type I-F CRISPR RNA guided
1056 surveillance complex bound to transposition protein TniQ. *Cell Res.* **30**, 179–181 (2020).
- 1057 44. Zhong, E. D., Bepler, T., Berger, B. & Davis, J. H. CryoDRGN: reconstruction of
1058 heterogeneous cryo-EM structures using neural networks. *Nat. Methods* **18**, 176–185
1059 (2021).
- 1060 45. Moreb, E. A., Hutmacher, M. & Lynch, M. D. CRISPR-Cas ‘non-Target’ Sites Inhibit On-
1061 Target Cutting Rates. *CRISPR J.* **3**, 550–561 (2020).
- 1062 46. Tuminauskaite, D. *et al.* DNA interference is controlled by R-loop length in a type I-F1
1063 CRISPR-Cas system. *BMC Biol.* **18**, 1–16 (2020).

- 1064 47. Rollins, M. C. F. *et al.* Structure Reveals a Mechanism of CRISPR-RNA-Guided Nuclease
1065 Recruitment and Anti-CRISPR Viral Mimicry. *Mol. Cell* **74**, 132-142.e5 (2019).
- 1066 48. Guo, T. W. *et al.* Cryo-EM Structures Reveal Mechanism and Inhibition of DNA Targeting by
1067 a CRISPR-Cas Surveillance Complex. *Cell* **171**, 414-426.e12 (2017).
- 1068 49. Chowdhury, S. *et al.* Structure Reveals Mechanisms of Viral Suppressors that Intercept a
1069 CRISPR RNA-Guided Surveillance Complex. *Cell* **169**, 47-57.e11 (2017).
- 1070 50. Wang, Y. *et al.* A novel strategy to engineer DNA polymerases for enhanced processivity
1071 and improved performance in vitro. *Nucleic Acids Res.* **32**, 1197–1207 (2004).
- 1072 51. de Vega, M., Lázaro, J. M., Mencía, M., Blanco, L. & Salas, M. Improvement of ϕ 29 DNA
1073 polymerase amplification performance by fusion of DNA binding motifs. *Proc. Natl. Acad.*
1074 *Sci. U. S. A.* **107**, 16506–16511 (2010).
- 1075 52. Oscorbin, I. P., Wong, P. F., Boyarskikh, U. A., Khrapov, E. A. & Filipenko, M. L. The
1076 attachment of a DNA-binding Sso7d-like protein improves processivity and resistance to
1077 inhibitors of M-MuLV reverse transcriptase. *FEBS Lett.* **594**, 4338–4356 (2020).
- 1078 53. Tong, C. L., Kanwar, N., Morrone, D. J. & Seelig, B. Nature-inspired engineering of an
1079 artificial ligase enzyme by domain fusion. *Nucleic Acids Res.* **50**, 11175–11185 (2022).
- 1080 54. Jackson, R. N. *et al.* Crystal structure of the CRISPR RNA-guided surveillance complex
1081 from *Escherichia coli*. *Science* **345**, 1473–1479 (2014).
- 1082 55. Xue, C., Zhu, Y., Zhang, X., Shin, Y. K. & Sashital, D. G. Real-Time Observation of Target
1083 Search by the CRISPR Surveillance Complex Cascade. *Cell Rep.* **21**, 3717–3727 (2017).
- 1084 56. Aldag, P. *et al.* Dynamic interplay between target search and recognition for a Type I
1085 CRISPR-Cas system. *Nat. Commun.* **14**, (2023).
- 1086 57. Qi, L. S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific
1087 control of gene expression. *Cell* **152**, 1173–1183 (2013).
- 1088 58. Hoffmann, F. T. *et al.* Selective recruitment of the AAA + ATPase TnsC increases the fidelity
1089 of Type I-F CRISPR RNA-guided transposition. *Manuscr. Revis.* 1–60 (2021).

- 1090 59. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* **596**,
1091 583–589 (2021).
- 1092 60. Skelding, Z., Sarnovsky, R. & Craig, N. L. Formation of a nucleoprotein complex containing
1093 Tn7 and its target DNA regulates transposition initiation. *EMBO J.* **21**, 3494–3504 (2002).
- 1094 61. Zhang, F., Saito, M. & Faure, G. Type I-B CRISPR-Associated Transposase Systems.
1095 (2024).
- 1096 62. Metagenomi Technologies. S-1. (2024).
- 1097 63. Strecker, J., Zhang, F. & Ladha, A. CRISPR-associated transposase systems and methods
1098 of use thereof.
- 1099 64. Jamali, K. *et al.* Automated model building and protein identification in cryo-EM maps.
1100 *Nature* (2024) doi:10.1038/s41586-024-07215-4.
- 1101 65. Ondov, B. D., Bergman, N. H. & Phillippy, A. M. Krona-385.pdf. *BMC Bioinformatics* **385**,
1102 (2011).
- 1103 66. Kalichuk, V. *et al.* The archaeal “7 kDa DNA-binding” proteins: extended characterization of
1104 an old gifted family. *Sci. Rep.* **6**, 37274 (2016).
- 1105 67. Shao, X. Common fold in helix-hairpin-helix proteins. *Nucleic Acids Res.* **28**, 2643–2650
1106 (2000).
- 1107